

Introduction diabetes mellitus (dm) is a disorder

[Business](#), [Industries](#)



Introduction Diabetes mellitus (DM) is a disorder of the endocrine system, occurring as a result of the pancreas' inability to produce insulin (Type 1), or the body's capability to respond to insulin and/or impaired insulin production (Type 2). Poor regulation of blood glucose levels can lead to hyperglycaemia (high blood glucose), with early symptoms commonly presenting as increased thirst, hunger, urination, as well as blurred vision. Long term complications may manifest through vascular disease, impaired kidney function, optic and nerve damage, limb amputations as well as an increased susceptibility to infection. Heart disease remains to be the leading cause of mortality in DM1. T1DM is caused by autoimmune destruction of pancreatic beta cells responsible for insulin secretion, whereas T2DM is thought to have a number of risk factors, such as age, obesity, lack of exercise, as well as a genetic predisposition. There is currently no known cure for DM, and so management of the condition normally consists of a lifelong combination of dietary measures, exercise, as well as drugs which help to regulate blood glucose levels. This includes the injectable administration of insulin, and/or the use of oral medication which help to improve blood glucose regulation.

Diabetes was once thought of as a condition which only afflicted the affluent; however an increasing body of literature seems to suggest that this is no longer the case³⁵. Global Burden It is estimated that in 2014, there were around 422 million people living with diabetes, with 1.5 million deaths occurring in 2012 as a result of diabetes. An additional 2.2 million deaths have been attributed to cardiovascular disease, chronic kidney disease and tuberculosis related higher-than optimal blood glucose levels.

Over the past decade, diabetes prevalence has risen faster in low- and middle-income countries than in high-income countries, with no less than three-quarters of diabetics now living in these regions²⁶. The WHO's Eastern Mediterranean region currently bears the greatest prevalence of diabetes². This essay hopes to evaluate how factors such as access to quality health care, socio-economic development, as well as migration affect the burden of type 2 diabetes mellitus (as this type accounts for around 90-95% of diabetic cases globally⁴⁰), using research already undertaken in regions with relatively high prevalence rates, so as to inform policy making for nations where the burden is increasing, such as in Africa. The infrastructure of healthcare systems across Africa varies substantially, with many countries lacking adequate structural capability to effectively respond to the increasing burden of non-communicable diseases.

This is resulting from a combination of vertical and/or earmarked funding for certain diseases by external donors, as well as decisions to allocate funding and resources already available towards the management of acute conditions and infections. With vascular disease already being a leading cause of mortality worldwide³¹, it would be useful to take into consideration management strategies for diabetes, which could help to also reduce the global burden cardiovascular disease. A number of studies have also identified diabetes as increasing the risk of developing active tuberculosis³⁰. The global burden of diabetes is also important to consider then in the global fight against tuberculosis. Diabetes can also present a heavy burden economically, via direct costs to service users' pockets, to health systems and society, in addition to indirect costs attributable to

premature mortality, temporary disability and permanent disability attributable to secondary complications arising from the condition³⁹. Access to Quality Healthcare Definitions of 'access to health services' are variable ranging from the narrow focus approach of service entry to the multidimensional approach, which includes: availability, acceptability, affordability, and accommodation⁴. The delivery of effective therapy in relation to diabetes management requires several components; continuity of care, uninterrupted access to medicines and syringes, tools for diagnosis and follow-up, availability of trained healthcare workers, government policies and the role of diabetes associations¹⁰.

Limited access to healthcare can present a number of challenges to the management of diabetes, such as case detection and treatment delivery. Early case detection, for example can help to prevent the onset of long term complications arising from diabetes. Individuals with undiagnosed T1DM can remain so for years, and are considered to be at significantly higher risk of cardiovascular disease than individuals without; failure then in making a diagnosis could restrict one's access to treatment potentially resulting in death³. It is estimated that globally, around 45.

8% of all diabetes cases in adults are estimated to be undiagnosed¹¹. More than 80% of deaths from diabetes are currently occurring in developing countries, where access to proper healthcare and financial means are an implicating factor⁹. In addition to poor access to affordable insulin, diabetics in low and middle income countries can face wide price variations resulting from the complexity of supply chains, location of purchase, as well

as the manner by which it is purchased. For example, the price of insulin from a single producer can vary from US\$9 in Zimbabwe to over US\$44 in the Congo⁹. Affordable access to measurement tools which can be used in assessing long term glycaemic control, such as glycosylated haemoglobin concentrations (Hb1Ac) may also affect the quality of care that can be delivered by healthcare professionals³².

The undersupply, as well as oversupply of medication can also be associated with poor outcomes in health. In a study conducted by Chen and colleagues¹², only around 50% of diabetes patients followed up post-initial diagnosis, were receiving an appropriate supply of medication. The same study also identified that oversupply of medication could result in increased disease-related hospitalisations and emergency department visits, as well as an increased burden of cost.

Undersupply of medication was also found to increase disease related hospitalisation but for different reasons. Even when governments provide anti-diabetic medication free of charge for economically disadvantaged groups, in practice, many eligible patients do not have access to these schemes¹⁹. A systematic review by Paduch et al. ²⁰ identified a number of psycho-social barriers to healthcare use for individuals suffering from diabetes. These ranged from cultural beliefs that men should not care about their health, a preference for traditional healers²¹, and religious beliefs which may predispose individuals to fatalistic attitudes.

The decision to not pursue treatment, or opt for a therapy which may not provide adequate glycaemic control could then lead to deterioration in

health. One may initially consider the lack of refrigeration facilities to affect access to insulin which has not been affected by temperature (as this is normally kept in refrigeration). However, recent discussions have identified solutions to overcome this potential obstacle to delivering quality care⁴¹.

Migration may occur for various reasons: For voluntary migrants the desire or need to leave the country of origin may be stronger than the desire to stay, and/or the receiving country is in need of the type and class of labor that the migrants have to offer²⁹, whereas involuntary migration can occur due to displacement resulting from war, persecution, or natural disasters. Globally, the total number of migrants in 2015 exceeded 244 million and is not expected to reduce⁵, with healthcare systems in upper-middle and high income countries facing significant challenges in providing equitable, accessible and culturally competent healthcare for growing ethnic minority groups⁴. The relation between migration status and disease pattern is complex due to potential underlying factors related to their country of origin, their new host country, and possibly also by the migration process itself⁶.

Figure X highlights the various factors which may act as determinants towards developing T1DM¹⁷, as a result of migration. The World Health Organisation has identified migrant and refugee populations with non-communicable diseases to be at greater vulnerability of adverse events related to their condition. Forced displacement could result in disruption to the continuity of access to health and medication, loss of prescriptions, as well as irregular food supplies. Such circumstances could help to deteriorate the condition of individuals already suffering from diabetes. The legal, or documented status of a migrant, is one of the most important determinants

of the access of migrants to health services in a country¹⁶, where non-documented status may also result in the underutilisation of healthcare services³³. A number of studies have identified migrant populations to have a greater prevalence of T1DM in comparison to their host populations^{22, 23}.

Migrants may also be at greater risk of developing T1DM in relation to their native counterparts; migrant Asian Indians living in the UK were found to be more obese, to have higher blood pressure, total cholesterol, and blood glucose levels, and to be more insulin-resistant than their non-migrant siblings living in India³¹. Cultural and language barriers may also impair the capabilities of migrant populations to seek healthcare, or effectively utilise services where and when accessed. Lack of education regarding diabetes, poor understanding of host population health systems, and well as mistrust of healthcare professionals may also have a negative impact on undertaking preventative measures, service access, and treatment adherence¹⁸. The process of acculturation, which often occurs alongside migration, can result in changes to dietary habits of migrants which may increase their risk of developing T1DM. One trend which has been observed is an increased fat and overall energy intake, with a reduction in carbohydrates, as well as a switch from whole grains and pulses to more refined forms of carbohydrates^{27, 28}.

Migration may also occur domestically from rural to urban environments; the changes in lifestyle that this may bring may also be associated with an increased prevalence in T1DM³⁴. Rural migrants may also be less likely to access healthcare services (or experience greater difficulty in doing so)

compared to their urban counterparts³⁶. Socio-economic development Certain risk factors implicated in the development of diabetes are also known to be associated with socioeconomic status (SES). Obesity, physical inactivity, smoking, and low birth weight have all been described as risk factors for T1DM. In Western societies these factors have often been associated with low socioeconomic status¹⁵. DeSilva and colleagues have also acknowledged that in high income countries, prevalence, poor management and complications of diabetes exhibit a social gradient, with higher proportions observed among lower socioeconomic groups³⁷. Interestingly, in many developing and transitional countries, diabetes prevalence increases with SES whereas the reverse is true in developed nations²².

Around two thirds of diabetes patients live in urbanised areas, with those in the lower socio-economic classes being disproportionately affected. The reasons for this are still poorly understood, but healthier lifestyles may be considered as a contributing factor⁷. A study conducted in Spain found that the prevalence of T1DM in individuals with lower SES was reported as 2.17 times as much as other individuals, with the prevalence of obesity, sedentary lifestyle, and abnormal blood lipid concentrations also being found to be higher in T1DM patients of a lower socio-economic status⁸. The global rise in obesity has also been paralleled with an increase in the prevalence of T1DM¹⁴. With obesity often disproportionately affecting lower socio-economic classes, it is also important then to consider the impact of obesity and its role in the development of T1DM. Obesity can be caused by a number of factors, such as a high energy-dense diet, consuming highly processed foods (often

having high sugar and fat content), as well as lack of physical activity. The SES of an individual may exert an influence in propagating these risk factors.

An individual of lower SES may have less income available in order to source healthy foods at an affordable cost, or live in an area where there is a high concentration of fast food outlets, where fiscally cheap, nutrient poor foodstuffs are commonplace⁴⁴. Living in such an environment could incline the individual regularly consume such foods, thereby increasing their risk of developing obesity, and potentially T1DM as a consequence of such lifestyle choices. In many countries diabetes may demand a large financial burden on the individual and their families, leading households into poverty. For example in Sudan the total median cost for diabetes care was US\$283, of which one third was spent on insulin¹³.³⁷.

9% of Ugandan diabetes patients also resorted to missing and omitting medication due to not being able to afford it¹⁹. Increased SES may also help to improve access to medicines; Christiani and colleagues¹⁹ found high income groups in a region of rural southwestern China were more likely to be treated with any anti-diabetic medication, than those of a lower income group. Tao and co-workers on the other hand, found decreased SES being associated with poor metabolic control, as well as a greater incidence of diabetes-related complications³⁸. Global Health Actors There are a number of global health actors currently working towards combatting the growing global diabetes epidemic: Pharmaceutical Industry With medication being an integral component to the management of diabetes post-onset, the

diabetes epidemic would naturally be of concern to the pharmaceutical industry for a number of reasons.

Novo Nordisk is a pharmaceutical company of Danish origins, having a historical base in insulin manufacture, and currently provides around a half of the world's insulin²⁴. The company currently outlines a number of commitments in their 'Access to Health' approach²⁵, with a focus on improving accessibility, affordability, availability to insulin therapy in resource poor settings, as well as advocating equal rights and accessibility to healthcare. Sanofi, another leading pharmaceutical company in the field of diabetes, currently supports a wide range of programs globally which involve engaging with civil society organisations²⁶.

The focus of these programs vary according to the needs of the populations where they are being conducted, however the majority of these initiatives place emphasis on education and promotion of prevention strategies for the condition. It has also undertaken partnerships with other pharmaceutical companies in order to further development of novel oral-anti-diabetic agents.

World Health Organisation The contributions of WHO towards tackling the global diabetes epidemic is mainly focused on advocacy, as well as the provision of technical guidance. WHO published its very first report on the global burden of diabetes in 2016², where it identified a number of measures which can be implemented by governments in order to address the epidemic, calling on other arms of governance such as trade and agriculture to consider the impact their policies will have on health.

Access to essential medicines such as insulin, lipid-modifying, anti-hypertensive, and anti-diabetic medication have also been recognised to not always be readily available in low and middle-income countries, as well as the availability of basic diagnostic tools to facilitate early case detection. The WHO also operates a program specifically dedicated to the promotion of health of migrant populations⁴². A resolution was passed on the 29th May 2017, urging member states to consider the promotion of a framework containing priorities and guiding principles in order to promote the health of refugees and migrants. The WHO Essential Medicines and Health Products (EMP) Department works with countries to promote affordable access to quality, safe and effective medicines, vaccines, diagnostics and other medical devices. Built on three main pillars - access, innovation and regulation - EMP promotes policies and technical capacities in low-resourced health systems, develops international standards for the manufacturing and regulation of health products and provides guidance for health systems everywhere to deliver them safely and cost-effectively⁴⁵. Non-State Actors There are also a number of non-state actors which are involved in dealing with diabetes.

The International Diabetes Federation (IDF) is an umbrella organization of over 230 national diabetes associations in 170 countries and territories²⁷. Much of their work involves advocacy, as well as conducting research, the compilation of evidence based guidelines and epidemiological studies (allowing for the publication of resources such as the IDF Diabetes Atlas), with an aim to facilitate policy making and care delivery. The IDF also conducted a report in 2016 on the perspective of people and healthcare professionals on the access to medicines and supplies for people with diabetes. The

International Insulin Foundation (IFF) is an organisation which conducts activities which are specific to improving access to insulin for populations that require it. The IIF has developed tools to assess access, such as the RAPIA (Rapid Assessment Protocol for Insulin Access)⁴⁶, as well as undertake research collaborations with other organisations so as to inform key-stakeholders in low and middle-income countries.

The World Diabetes Foundation is an organisation whose work focuses on reach the poorest populations suffering from diabetes globally. Their activities can be divided into three main categories; improving access to diabetes care, promoting primary prevention and awareness, as well as advocacy. Projects are undertaken around the world in under a 'focus area', of which include tackling T1DM through various measures such as improving care access, as well as the double burden of diabetes and tuberculosis⁴⁷. National Governments around the world have undertaken a wide range of approaches to contributory social security schemes, employer-based health insurance and tax-based schemes to improve migrants' health and access to health services. For example, some countries of migrant origin that heavily rely on remittances, such as Sri Lanka and the Philippines, put in place insurance schemes for their overseas migrant workers. Countries of migrant destination, including Thailand, offer health services to certain categories of registered migrants and their families through a compulsory migrant health scheme. Brazil, Spain and Portugal are examples of countries that have adopted a policy of equal access to coverage for all migrants irrespective of their legal status.

Other initiatives are led by trade unions and employees. For instance, in Argentina, employers of rural migrant workers contribute a percentage of their workers' salaries towards a special fund that covers social benefits, including health insurance⁴³. Although these interventions may not be inherently directed towards tackling diabetes, measures such as what has been outlined above would help to improve access to health services in general. Some governments have taken an approach to policy making which considers its impact on health, such as in Australia. South Australia has implemented a health-in-all-policies approach, which emphasises that government objectives for a healthy population are best achieved when all sectors include health and wellbeing as a key component of policy development⁴⁴.

Conclusion and Recommendations

The increasing global burden of diabetes is something which has only been recently acknowledged by the World Health Organisation.

However, due to the numerous long term complications that can arise from poor diabetes management, both in terms of financial cost and health, diabetes is a condition which should be taken with serious consideration. Much work is being done to improve access to diabetes care around the world, especially by non-state actors, but national governments must also take responsibility in ensuring that adequate care can reach populations in need. National governments can also play an important role in shaping policy in such a way that always prioritises the health of its population, as well as improve the socio-economic status of its citizens. Addressing other health epidemics such as obesity through the use of frameworks such as the World Cancer Research Fund International's

NOURISHING framework⁴⁴ may help to alleviate the future burden of diabetes. The delivery care of migrant populations may prove to be a challenge for several reasons, be that due to language or cultural barriers, or their temporary status, but one may consider from an ethical perspective that quality care should be provided as a moral duty, especially if the same level can be easily delivered to its own citizens.